Medtronic launching Freestyle stentless porcine heart valve at a premium to St. Jude's Toronto SPV.
This article was originally published in The Gray Sheet
Executive Summary
MEDTRONIC PRICING FREESTYLE VALVE AT PREMIUM TO ST. JUDE's TORONTO SPV, indicating a belief that the "advanced tissue technology" gives Medtronic an edge over its only competitor in the U.S. stentless porcine heart valve market. Premarket approval applications for the Medtronic and St. Jude stentless porcine heart valves cleared FDA on Nov. 25 and Nov. 24, respectively.